 The investigators hypothesis is that the administration of Fluzone High-Dose with booster to all patients with monoclonal gammopathies irrespective of age will lead to seroconversion rates exceeding 50 and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer therapy and may reduce disease progression at the end of the flu season 